These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Cost-effectiveness analysis of abrocitinib compared with standard of care in adult moderate-to-severe atopic dermatitis in Japan. Tanaka A; Yuasa A; Kamei K; Nagano M; Murofushi T; Bjerke A; Nakamura K; Ikeda S J Dermatol; 2024 Jun; 51(6):759-771. PubMed ID: 38650307 [TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of sotagliflozin for the treatment of patients with diabetes and recent worsening heart failure. Kim J; Wang S; Sikirica S; Shafrin J J Comp Eff Res; 2024 Jun; 13(6):e230190. PubMed ID: 38771012 [No Abstract] [Full Text] [Related]
4. Cost-utility analysis of an alcohol policy in Thailand: a case study of a random breath testing intervention. Vichitkunakorn P; Khampang R; Leelahavarong P; Nontarak J; Assanangkornchai S BMC Health Serv Res; 2024 Jun; 24(1):739. PubMed ID: 38886718 [TBL] [Abstract][Full Text] [Related]
5. Cost-Effectiveness of Sotagliflozin in SOLOIST-WHF. Weintraub WS; Kolm P; Dolman S; Alva M; Bhatt DL; Zhang Z JACC Heart Fail; 2024 Jun; ():. PubMed ID: 38878007 [TBL] [Abstract][Full Text] [Related]
6. Cost-Effectiveness of Implantable Pulmonary Artery Pressure Monitoring in Chronic Heart Failure. Sandhu AT; Goldhaber-Fiebert JD; Owens DK; Turakhia MP; Kaiser DW; Heidenreich PA JACC Heart Fail; 2016 May; 4(5):368-75. PubMed ID: 26874380 [TBL] [Abstract][Full Text] [Related]
7. Decision tree-Markov model of perinatal depression screening: a cost-utility analysis. Yang Y; Zheng R; Yang L; Huang X; Zhang T Front Public Health; 2024; 12():1308867. PubMed ID: 38832225 [TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness Analysis of Fluocinolone Acetonide Intravitreal (FAI) Implant for Chronic Noninfectious Uveitis Affecting the Posterior Segment of the Eye (NIU-PS) in China. Mao X; Dai Z; Yang J; Wu Y; Xie F; Lu Y; Yu J; Chang F; Lu Y Ophthalmol Ther; 2024 Jun; 13(6):1757-1772. PubMed ID: 38676875 [TBL] [Abstract][Full Text] [Related]
9. Clinical Pharmacokinetic and Pharmacodynamic Profile of Vericiguat. Fritsch A; Meyer M; Blaustein RO; Trujillo ME; Kauh E; Roessig L; Boettcher M; Becker C Clin Pharmacokinet; 2024 Jun; 63(6):751-771. PubMed ID: 38916717 [TBL] [Abstract][Full Text] [Related]
10. Supplemental Optoacoustic Imaging of Breast Masses: A Cost-Effectiveness Analysis. Ozcan BB; Xi Y; Dogan BE Acad Radiol; 2024 Jan; 31(1):121-130. PubMed ID: 37748954 [TBL] [Abstract][Full Text] [Related]
11. Vericiguat and Cardiovascular Outcomes in Heart Failure by Baseline Diabetes Status: Insights From the VICTORIA Trial. Khan MS; Butler J; Young R; Lewis BS; Escobedo J; Refsgaard J; Reyes E; Roessig L; Blaustein RO; Lam CSP; Voors AA; Ponikowski P; Anstrom KJ; Armstrong PW; JACC Heart Fail; 2024 Jun; ():. PubMed ID: 38934967 [TBL] [Abstract][Full Text] [Related]
12. Towards the Fifth Pillar for the Treatment of Heart Failure with Reduced Ejection Fraction: Vericiguat in Older and Complex Patients. Spadafora L; Bernardi M; Sarto G; Simeone B; Forte M; D'Ambrosio L; Betti M; D'Amico A; Cammisotto V; Carnevale R; Bartimoccia S; Sabouret P; Zoccai GB; Frati G; Valenti V; Sciarretta S; Rocco E Am J Cardiovasc Drugs; 2024 Jul; 24(4):469-479. PubMed ID: 38856965 [TBL] [Abstract][Full Text] [Related]
13. Beyond quadruple therapy: the potential roles for ivabradine, vericiguat, and omecamtiv mecarbil in the therapeutic armamentarium. Shoji S; Mentz RJ Heart Fail Rev; 2024 Jun; ():. PubMed ID: 38951303 [TBL] [Abstract][Full Text] [Related]
15. Cost-utility analysis of prenatal diagnosis of congenital cardiac diseases using deep learning. Ginsberg GM; Drukker L; Pollak U; Brezis M Cost Eff Resour Alloc; 2024 May; 22(1):44. PubMed ID: 38773527 [TBL] [Abstract][Full Text] [Related]
16. Cost-Utility Analysis of Vericiguat in Heart Failure with Reduced Ejection Fraction After Worsening Heart Failure Events in China. Chen P; Wang Y; Liu X; Yu J; Zheng X Am J Cardiovasc Drugs; 2024 May; 24(3):445-454. PubMed ID: 38619802 [TBL] [Abstract][Full Text] [Related]
17. Cost-utility analysis of add-on vericiguat for the treatment of chronic heart failure with reduced ejection fraction in China. Wang L; Huo X; Sun H; Liu F; Huang R; Zhao Q BMC Public Health; 2024 May; 24(1):1275. PubMed ID: 38724960 [TBL] [Abstract][Full Text] [Related]
18. Cost-Effectiveness of Vericiguat in Patients With Heart Failure With Reduced Ejection Fraction: The VICTORIA Randomized Clinical Trial. Chew DS; Li Y; Bigelow R; Cowper PA; Anstrom KJ; Daniels MR; Davidson-Ray L; Hernandez AF; O'Connor CM; Armstrong PW; Mark DB; Circulation; 2023 Oct; 148(14):1087-1098. PubMed ID: 37671551 [TBL] [Abstract][Full Text] [Related]
19. Cost Effectiveness of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event from a US Medicare Perspective. Alsumali A; Djatche LM; Briggs A; Liu R; Diakite I; Patel D; Wang Y; Lautsch D Pharmacoeconomics; 2021 Nov; 39(11):1343-1354. PubMed ID: 34623625 [TBL] [Abstract][Full Text] [Related]